ライフサイエンスコーパス: transthoracic echocardiography

1 s underwent baseline clinical evaluation and transthoracic echocardiography.

2 dural hemodynamic parameters were studied by transthoracic echocardiography.

3 with ICE despite being underrecognized with transthoracic echocardiography.

4 and normal right-sided cardiac morphology by transthoracic echocardiography.

5 The presence of PFO was assessed by transthoracic echocardiography.

6 compared with other imaging modalities, even transthoracic echocardiography.

7 cation and aortic stenosis was determined by transthoracic echocardiography.

8 of nuclear extracts) and cardiac function by transthoracic echocardiography.

9 peratively in only 5 of 41 (12%) patients by transthoracic echocardiography.

10 em agreed to undergo electrocardiography and transthoracic echocardiography.

11 tening, as revealed by gated cardiac MRI and transthoracic echocardiography.

12 y biplane and volumetric (three-dimensional) transthoracic echocardiography.

13 etermine the prevalence of the problem using transthoracic echocardiography.

14 o intensive care, they were reassessed using transthoracic echocardiography.

15 sclerosis Risk in Communities) who underwent transthoracic echocardiography.

16 speckle tracking was assessed with same-day transthoracic echocardiography.

17 tertile [LAA], respectively) as measured by transthoracic echocardiography.

18 under a deep standardized inspiration using transthoracic echocardiography.

19 s recently emerged as an ideal complement to transthoracic echocardiography.

20 ed by serial right heart catheterization and transthoracic echocardiography.

21 ively evaluated their proficiency in focused transthoracic echocardiography.

22 res of the valve and ventricular function by transthoracic echocardiography.

23 nsional (2D) and 3D (automated true 3D PISA) transthoracic echocardiography.

24 c valve gradient and ventricular function by transthoracic echocardiography.

25 ty using real-time volume color flow Doppler transthoracic echocardiography.

26 -240 kg) without cardiac disease by standard transthoracic echocardiography.

27 us (>16 days) Q-wave MI by ECG who underwent transthoracic echocardiography: 194 with IMR quantitativ

28 osis of endocarditis (14%-28%) compared with transthoracic echocardiography (2%-15%).

29 prospectively performed using 2-dimensional transthoracic echocardiography (2D-TTE) in 282 patients

30 m to evaluate the ability of two-dimensional transthoracic echocardiography (2D-TTE) to determine cau

31 cular MR (CMR) and 2-dimensional (2D) and 3D transthoracic echocardiography (2DTTE and 3DTTE) were pe

32 longer than agitated saline bubble-enhanced transthoracic echocardiography (3.2 min) (p < 0.001).

33 d Task Force Criteria and underwent baseline transthoracic echocardiography, 37 (53%) patients experi

34 clinical assessment, chest radiography, and transthoracic echocardiography, a panel of three cardiol

35 isit 5 examination (2011-2013) and underwent transthoracic echocardiography (age, 75+/-6 years; 61% w

36 Transthoracic echocardiography, alone or in sequence wit

37 , population-based cohort, PFO detected with transthoracic echocardiography and agitated saline was n

38 ography, hemodynamic data were obtained from transthoracic echocardiography and cardiac catheterizati

39 atients were characterized with conventional transthoracic echocardiography and cardiac magnetic reso

40 e normal global cardiac function by standard transthoracic echocardiography and CMR measures.

41 , despite normal global systolic function by transthoracic echocardiography and CMR.

42 dentified by agitated saline bubble-enhanced transthoracic echocardiography and confirmed by chest ra

43 Using transthoracic echocardiography and coronary computed tom

44 ch fellow's knowledge with regard to focused transthoracic echocardiography and each fellow's ability

45 n-Meier estimates, the time between baseline transthoracic echocardiography and experiencing MACE was

46 opulmonary hypertension may be screened with transthoracic echocardiography and following up with a r

47 Indexes from transthoracic echocardiography and hemodynamic evaluatio

48 y and the recently developed tri-dimensional transthoracic echocardiography and intracardiac echocard

49 ine-stimulated cardiac function, measured by transthoracic echocardiography and left ventricular micr

50 Transthoracic echocardiography and lung ultrasound are n

51 We hypothesize that a combination of transthoracic echocardiography and lung ultrasound is no

52 Transthoracic echocardiography and measurement of B-type

53 Transthoracic echocardiography and MRI are noninvasive i

54 ocardial depression measured by quantitative transthoracic echocardiography and peak inotrope require

55 venues and pathologies, ranging from surface transthoracic echocardiography and portable hand-held ec

56 mpared the results of pre- and postoperative transthoracic echocardiography and right heart catheteri

57 s is generally performed using 2-dimensional transthoracic echocardiography and TEE.

58 -matched control subjects underwent contrast transthoracic echocardiography and transcranial Doppler

59 hocardiography from the typical platforms of transthoracic echocardiography and transesophageal echoc

60 ft ventricular mass index (LVMI) measured by transthoracic echocardiography and, in a subset, by card

61 , 16.7% of patients with E-BSI who underwent transthoracic echocardiography, and 35.5% of all patient

62 n, and late gadolinium enhancement imaging), transthoracic echocardiography, and applanation tonometr

63 llowed by comprehensive clinical evaluation, transthoracic echocardiography, and clinical genetic tes

64 pected infective endocarditis should undergo transthoracic echocardiography, and most of these patien

65 m) study underwent psychometric assessments, transthoracic echocardiography, and platelet aggregation

66 sleep function by pulmonary function tests, transthoracic echocardiography, and polysomnography 3 mo

67 plethysmography, bioimpedance cardiography, transthoracic echocardiography, and sphygmomanometry, re

68 entricular ejection fraction (LVEF) >/=8% by transthoracic echocardiography, and/or ischemic ST-segme

69 Transthoracic echocardiography, aortic catheterization,

70 Mobile thrombi, not routinely recognized on transthoracic echocardiography, are frequently identifie

71 individuals with TS age 7 to 67 years using transthoracic echocardiography as our primary screening

72 n, ultrasound-guided regional anesthesia and transthoracic echocardiography as well as expand on a va

73 ts undergoing aortic valve repair, follow-up transthoracic echocardiography at a median of three mont

74 All patients who underwent outpatient transthoracic echocardiography at a university-based ter

75 cognized as more sensitive and specific than transthoracic echocardiography at detecting vegetations

76 l septal defect (SVD) is underdiagnosed with transthoracic echocardiography because of its posterior

77 Cardiac function was assessed by transthoracic echocardiography before fluid administrati

78 The remaining animals underwent transthoracic echocardiography before surgery and 7 days

79 Hemodynamic parameters, transthoracic echocardiography, biological data, and ele

80 Transthoracic echocardiography can visualize the left ve

81 Transthoracic echocardiography cannot reliably detect th

82 Five studies identified clinical or transthoracic echocardiography characteristics associate

83 Prior transthoracic echocardiography clearly defined the SVD i

84 Subjects underwent transthoracic echocardiography, CMR with routine cine ac

85 Transthoracic echocardiography could not visualize the a

86 We designed and implemented a focused transthoracic echocardiography curriculum for critical c

87 A focused transthoracic echocardiography curriculum that includes

88 unctional analysis of Cav-1/3 dKO hearts via transthoracic echocardiography demonstrates hypertrophy

89 d flow propagation velocity were assessed by transthoracic echocardiography during a prolonged intrac

90 Subcostal transthoracic echocardiography during catheter insertion

91 y (76+/-5 years and 60% women) who underwent transthoracic echocardiography, excluding former drinker

92 In 4 studies, clinical or transthoracic echocardiography findings did not predict

93 ity was assessed as being moderate at 30-day transthoracic echocardiography follow-up in all patients

94 Cardiac performance was assessed by transthoracic echocardiography following experimental ba

95 s to their presence, that TEE is superior to transthoracic echocardiography for detecting left atrial

96 ese studies provide the first application of transthoracic echocardiography for morphological/functio

97 All subjects underwent transthoracic echocardiography for significant valvular

98 egurgitant jet velocity >/=3.2 m/s (3.6%) on transthoracic echocardiography further underwent right h

99 ulmonary artery pressure (sPAP) estimated in transthoracic echocardiography: group I, sPAP <40 mm Hg

100 Two-dimensional transthoracic echocardiography has been used to study pa

101 essential for triage; however, comprehensive transthoracic echocardiography has limited availability.

102 ated whether two-dimensional high-resolution transthoracic echocardiography (HR-2DTTE) can detect cha

103 may provide a non-invasive alternative when transthoracic echocardiography image quality is insuffic

104 cine fellows to obtain and interpret focused transthoracic echocardiography images from critically il

105 w's ability to interpret prerecorded focused transthoracic echocardiography images.

106 y was to determine whether contrast-enhanced transthoracic echocardiography improves the evaluation o

107 We performed supine and upright transthoracic echocardiography in 118 patients with unex

108 We performed resting transthoracic echocardiography in 855 subjects with coro

109 ith altered cardiac function, as assessed by transthoracic echocardiography in conscious mice.

110 icular function as measured by 2-dimensional transthoracic echocardiography in contrast to 67.1% in c

111 To date, no studies have defined the role of transthoracic echocardiography in evaluating long-term m

112 in 26 of 86 patients (30%) but were seen on transthoracic echocardiography in only 1 of the 26 patie

113 Our data advocate a role for transthoracic echocardiography in risk stratification in

114 rated alternative to invasive techniques and transthoracic echocardiography in the assessment of aort

115 Mean pulmonary artery pressure, estimated by transthoracic echocardiography, increased after transfus

116 Transthoracic echocardiography indicated reverse LV remo

117 accuracy of agitated saline bubble-enhanced transthoracic echocardiography is equivalent to the ches

118 The frequency of valvular monitoring by transthoracic echocardiography is guided by the disease

119 Although transthoracic echocardiography is often sufficient for t

120 After TAVI, transthoracic echocardiography is performed to assess tr

121 Transthoracic echocardiography is the principal method c

122 Using transthoracic echocardiography, left ventricular fractio

123 Transthoracic echocardiography (M-mode and Doppler) offe

124 rior vena cava diameter (IVC) measured using transthoracic echocardiography, of the maximal Doppler v

125 However, transthoracic echocardiography often produces poor-quali

126 Patients underwent adenosine transthoracic echocardiography on two occasions--immedia

127 erload or suspected intracardiac shunting by transthoracic echocardiography or intraoperatively.

128 12 months of follow-up assessed both through transthoracic echocardiography (P=0.0167 versus baseline

129 BMI measured on admission, and 2-dimensional transthoracic echocardiography performed within 48 hours

130 Transthoracic echocardiography provides a practical meth

131 determined whether Doppler and 2-dimensional transthoracic echocardiography reliably assess hemodynam

132 Transthoracic echocardiography remains a primary tool fo

133 Transthoracic echocardiography revealed a mean+/-SD ejec

134 Transthoracic echocardiography revealed a normal tricusp

135 Transthoracic echocardiography revealed an irregular rig

136 Transthoracic echocardiography revealed MR only in the h

137 Transthoracic echocardiography showed a significantly in

138 At 30 days, transthoracic echocardiography showed mild (1+) central

139 ages from critically ill patients and a from transthoracic echocardiography simulator.

140 Transthoracic echocardiography, stress echocardiography,

141 Transthoracic echocardiography, TEE and TCD have been us

142 Using transthoracic echocardiography, there may be technical i

143 All subjects underwent transthoracic echocardiography to determine Doppler vari

144 Development of hypertrophy was followed by transthoracic echocardiography to measure left ventricul

145 tion (standard 12-lead electrocardiogram and transthoracic echocardiography) to the cardiology depart

146 sts of nine diagnostic strategies, including transthoracic echocardiography, transesophageal echocard

147 apparent improvements in appropriateness for transthoracic echocardiography (TTE) (80% [95% confidenc

148 ention of endocarditis included a systematic transthoracic echocardiography (TTE) and a 12-month cour

149 Both transthoracic echocardiography (TTE) and cardiac magneti

150 left ventricular mass (LVM) regression with transthoracic echocardiography (TTE) and magnetic resona

151 It is unclear whether Doppler transthoracic echocardiography (TTE) and transesophageal

152 f three strategies: 1) conventional therapy--transthoracic echocardiography (TTE) and warfarin therap

153 umenting its accuracy compared with standard transthoracic echocardiography (TTE) are not available.

154 rred for pharmacological stress testing with transthoracic echocardiography (TTE) are unable to under

155 The value of performing transthoracic echocardiography (TTE) as part of the clin

156 lobal LV function and RWM were compared with transthoracic echocardiography (TTE) by using multidetec

157 ence range for PASP as determined by Doppler transthoracic echocardiography (TTE) from a clinical ech

158 teria (AUC) for initial pediatric outpatient transthoracic echocardiography (TTE) have not yet been e

159 fit of cardiac magnetic resonance (CMR) over transthoracic echocardiography (TTE) in ischemic cardiom

160 The diagnostic value of transthoracic echocardiography (TTE) in the detection of

161 ional initiatives have been shown to improve transthoracic echocardiography (TTE) ordering practices

162 They received transthoracic echocardiography (TTE) to detect or exclud

163 vascular magnetic resonance (MR) imaging and transthoracic echocardiography (TTE) were performed in 1

164 before CABG, and 68 (50%) had postoperative transthoracic echocardiography (TTE) within 6 weeks of s

165 that for the diagnosis of endocarditis, (1) transthoracic echocardiography (TTE) would be most valua

166 METHODS AND After baseline transthoracic echocardiography (TTE), adult ICR mice wer

167 on, (b) feasibility and usefulness of repeat transthoracic echocardiography (TTE), and (c) whether th

168 tomic and functional sizing of a PFO include transthoracic echocardiography (TTE), transesophageal ec

169 g), and nine were diagnosed prospectively by transthoracic echocardiography (TTE).

170 valvular lesions in 802 patients undergoing transthoracic echocardiography using logistic regression

171 ch patient underwent electrocardiography and transthoracic echocardiography.Valvular disease was comm

172 ble to rapidly obtain five essential focused transthoracic echocardiography views: parasternal long a

173 nce between goal-directed echocardiogram and transthoracic echocardiography was 21 hours 18 minutes.

174 A protocol using transthoracic echocardiography was designed to diagnose

175 l examination and history were obtained, and transthoracic echocardiography was performed according t

176 Transthoracic echocardiography was performed at baseline

177 Two-dimensional transthoracic echocardiography was performed in 1818 par

178 Postprocedural transthoracic echocardiography was performed in 2769 (92

179 Transthoracic echocardiography was performed in 38 patie

180 Gold standard transthoracic echocardiography was performed on schedule

181 Clinical events were recorded and a transthoracic echocardiography was performed to evaluate

182 Transthoracic echocardiography was used in a protocol de

183 Standard transthoracic echocardiography was used to obtain apical

184 t 30 days and 6 months, assessed by contrast transthoracic echocardiography, was 48 (92%) of 52 and 5

185 Cardiac auscultation and transthoracic echocardiography were performed by 2 indep

186 microspheres) and regional wall thickening (transthoracic echocardiography) were measured in pigs st

187 Transthoracic echocardiography, which combines structura

188 assessment of MR has been with 2-dimensional transthoracic echocardiography, which is often used as a

189 llowed by an agitated saline bubble-enhanced transthoracic echocardiography, which was used to locali

190 PFO presence was assessed by transthoracic echocardiography with saline contrast inje

191 The advancement of transthoracic echocardiography with tissue Doppler imagi

192 easure of heart failure by a novel method of transthoracic echocardiography (with intravascular ultra

193 or 21-mm St Jude Medical prostheses and had transthoracic echocardiography within 1 year after AVR.

194 atheterization to evaluate AS also underwent transthoracic echocardiography within 24 hours.

195 grams, 110 with complete cardiology-reviewed transthoracic echocardiography within 48 hours for compa

196 tral annular velocities (e') with the use of transthoracic echocardiography within 48 hours of cardia

197 f a significant shunt cannot be ruled out by transthoracic echocardiography without the use of bubble

198 ening first-degree relatives for AAOCA using transthoracic echocardiography would be the prudent appr